Adamas Pharmaceuticals, Inc.
11
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
18.2%
2 terminated/withdrawn out of 11 trials
81.8%
-4.7% vs industry average
73%
8 trials in Phase 3/4
100%
9 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease
Role: collaborator
Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.
Role: lead
Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID
Role: lead
A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Role: lead
Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment
Role: lead
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Role: lead
ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
Role: lead
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
Role: lead
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Role: lead
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Role: lead
Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects
Role: lead
All 11 trials loaded